... strong (r² = 0.04 and mean F-statistics = 102). All estimates are expressed per 1 SD lower plasma levels of either APOC3 or PCSK9 to reflect the potential effect of drugs targeting their circulating levels. The strength of every instrument was evaluated with the Cragg–Donald...

...–12.9%). A total of 38.7% of children achieved the LDL-C goal, 23.9% fell short by up to 10%, 10.7% experienced moderate failure (were over the LDL-C target between >10% and 20%), and 26.7% failed by more than 20% to reach the LDL-C target. When comparing different regions, only Sweden and Greece...

... progression in the complex haemodynamic environment. Here, advances in efforts to understand the pathogenesis of CAVD and to identify putative drug targets derived from recent multi-omics studies [including (epi)genomics, transcriptomics, proteomics, and metabolomics] of blood and valvular tissues...

... of the study (December 2018), whichever came first. Corresponding author. Tel: +8617338896101, Email: [email protected] Corresponding author. Tel: +4640391382, Emails: [email protected] & [email protected] Phosphodiesterases Ischaemic heart disease Drug target Mendelian randomization...

... The study presents novel findings, being the first to establish the involvement of lumican in mediating H3 histone lactylation, thus facilitating the development of aortic valve calcification. Consequently, lumican would be a promising therapeutic target for intervention in the treatment of CAVD. Structured...

... of cloning, censoring, and weighting were applied to emulate the target trial. Patients were followed up for up to 30 days. The primary outcome was all-cause death. Among 780 matched patients (median age, 81 years), the adjusted hazard ratio was 1.11 (95% confidence interval 0.75–1.64, P = 0.59...

... of patients worldwide to prevent blood clots. Yet, problems with anticoagulant therapy remain, including a persistent and cumulative bleeding risk in patients undergoing prolonged anticoagulation. New safer anticoagulant targets are needed. Methods and results To prioritize anticoagulant targets...

... of the risk groups is as follows: low risk, ≤2%; medium risk, 2%–9%; high risk, 10%–19%; and very high risk ≥20%. ¹⁹ While future research is required to validate the HFA-ICOS risk assessment tool (except for the score dedicated to HER2 target therapies, which was validated by Battisti et...

... disease (CHD), stroke, or transient ischaemic attack at baseline or who experienced any form of MVE during the follow-up period. The main non-vascular outcomes were as previously used for a drug target Mendelian randomization study of CETP. ¹⁵ These were organized by anatomical site...

... studies. This study used time-in-target range (TTR) to measure the long-term PA level during young adulthood and investigated its relationship with cardiovascular events in later life. Methods and results Participants in the Coronary Artery Risk Development in Young Adults study were recruited...

...-making in this setting. Methods and results Five different ML models [gradient boosting classifier (GBC), linear discrimination analysis, Naïve Bayes, logistic regression, and K-nearest neighbours algorithm) for the prediction of 1-year target lesion failure (TLF) were trained on an extensive data...

...Hélène Singeisen; Frida Renström; Markus Laimer; Roger Lehmann; Stefan Bilz; Michael Brändle; on behalf of the SwissDiab Study Group The theoretical intensification of the current lipid-lowering medication needed for each patient to reach the 2016 and 2019 ESC/EAS LDL-C target was estimated...

... in target range (TTR) and test its independent association with cardiovascular outcomes. Methods and results We included 4468 adults from the Look AHEAD (Action for Health in Diabetes) trial. Body weight TTR was defined as the percentage of time during which body weight was within the Look AHEAD weight...

..., Standard Journals Publication Model ( https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights ) Abstract Aims Short-term blood pressure (BP) time in target range (TTR) independently predicts cardiovascular (CV) outcomes in adults. However, there are limited data regarding long-term TTR for BP...

... threshold for blood pressure (BP) in high-risk patients, such as those with chronic coronary syndromes (CCS), to a systolic BP of ≥130 mmHg and a diastolic BP of ≥80 mmHg (US guidelines ¹ ) or 85 mmHg (European guidelines, ² ) with an optimal BP target of <130/80 mmHg. The European...

... intervention (PCI) (P = 0.034) or target temperature management (TTM) (P < 0.001). Stepwise multivariable logistic regression analysis revealed that the call-to-ECPR interval was an independent predictor of favourable neurological outcome [odds ratio (OR) 0.96, 95% confidence interval (CI...

... correlation with increased aortic stiffness and higher central blood pressure. Funding Acknowledgement Type of funding sources: None. Target Organ Damage/Left Ventricular Hypertrophy 2298 Hypertension Pathophysiology and Mechanisms, Target Organ Damage / Left Ventricular Hypertrophy Correlation arterial...

... Educational Institution of Higher Education “The Volgograd State Medical University” of the Ministry of Health of the Russian Federation Target Organ Damage/Left Ventricular Hypertrophy Hypertension Pathophysiology and Mechanisms, Target Organ Damage / Left Ventricular Hypertrophy 2297 In uence of insulin...

... lesions, without a significant change in the CSF dynamics parameters (Table 1). Figure 1 shows a clinical example of a decrease in the number of fine focal brain lesions after the intervention. Funding Acknowledgement Type of funding sources: None. Target Organ Damage/Left Ventricular Hypertrophy 2294...

... not found in participants without IR. Conclusions IR may participate in the deterioration of CRF associated with LVH. Targeting IR in hypertensive patients with LVH could improve prognosis. Funding Acknowledgement Type of funding sources: None. Target Organ Damage/Left Ventricular Hypertrophy...